Does loss-of-function in the LDL receptor reduce hepatic LDL uptake and raise LDL cholesterol?

The mechanism by which the low-density lipoprotein receptor (LDLR) regulates cholesterol is one of the most thoroughly understood pathways in human physiology. Loss-of-function (LOF) in this pathway is the primary driver of Familial Hypercholesterolemia (FH) and age-related elevations in cholesterol.

Clinical and effectiveness evidence

Metabolic kinetic studies using radiolabeled tracers have established a direct causal link between hepatic clearance rates and plasma cholesterol levels.

• Clearance Rates: In individuals with normal cholesterol levels, the fractional catabolic rate (FCR) of LDL is typically around 0.57 pools/day. In contrast, patients with homozygous LOF mutations in the LDLR exhibit an FCR as low as 0.190 pools/day—a nearly 70% reduction in the body's ability to clear LDL particles.
• Impact on Plasma Levels: Mathematical modeling indicates that the clearance rate is the dominant determinant of serum LDL-C. Halving the hepatic clearance rate can raise plasma LDL-C by more than 100 mg/dL, even if the liver's production of new particles remains constant.
• Validation through Intervention: The clinical success of statins and PCSK9 inhibitors further supports this claim; these drugs lower cholesterol specifically by increasing the number of active LDL receptors on the hepatocyte surface, thereby accelerating clearance.

Mechanistic explanations

The liver is responsible for 70% to 90% of total systemic LDL catabolism. LOF mutations disrupt this process at the cellular level through several distinct pathways:

• Receptor Synthesis and Trafficking: Some LOF variants (Class 1 and 2) prevent the receptor from being synthesized or cause it to be trapped in the endoplasmic reticulum (ER), preventing it from reaching the cell surface.
• Binding and Internalization: Other mutations (Class 3 and 4) allow the receptor to reach the surface but impair its ability to bind to the apolipoprotein B-100 on the LDL particle or prevent the clathrin-dependent endocytosis of the receptor-LDL complex.
• Degradation Pathways: Gain-of-function in PCSK9, which degrades the LDL receptor, mimics these LOF mutations by reducing the receptor's availability for recycling, further demonstrating that receptor density on the hepatocyte surface is the critical rate-limiting step for cholesterol homeostasis.

Bottom line

Loss-of-function in the LDL receptor pathway directly impairs the liver's ability to remove LDL from circulation, which is the primary kinetic driver of elevated cholesterol; restoring this clearance mechanism remains the gold standard for reducing cardiovascular risk.